Cellectis S.A. (CLLS) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tonix Pharmaceuticals (TNXP) has outperformed Cellectis S.A. (CLLS) over the past year, losing 67.6% versus a loss of 70.9%. Over five years, CLLS leads with a -88.5% price change compared with -100.0% for TNXP. Cellectis S.A. is the larger company by market cap ($125.9 million vs $124.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | TNXP |
|---|---|---|
| Share price | $1.25 | $7.28 |
| Market cap | $125.90M | $124.86M |
| 1-day change | -6.72% | -3.58% |
| YTD return | -74.17% | -53.39% |
| 1-year return | -70.93% | -67.63% |
| 5-year return | -88.46% | -100.00% |
| EPS (TTM) | $-0.64 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $23.06 |
| 52-week low | $1.22 | $7.16 |
| Distance from 52-week high | -77.19% | -68.43% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +326.40% | +511.26% |
| Average volume | 78.59K | 537.49K |
| Shares outstanding | 72.72M | 17.15M |
| Employees | 224 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
CLLS vs TNXP FAQ
Which is bigger, Cellectis S.A. or Tonix Pharmaceuticals?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $125.90M compared with $124.86M for Tonix Pharmaceuticals (TNXP).
Which stock has performed better over the past year, CLLS or TNXP?
TNXP returned -67.63% over the past 12 months, compared with -70.93% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.